Orchestra BioMed Added to Russell 3000 and Russell 2000 Indexes
Event summary
- Orchestra BioMed added to the Russell 3000 and Russell 2000 indexes effective June 26, 2026.
- Inclusion follows the semi-annual reconstitution based on market capitalization rankings as of April 30, 2026.
- $12.2 trillion in assets are benchmarked against Russell's U.S. indexes.
- Orchestra BioMed's two flagship products, AVIM Therapy and Virtue SAB, are in pivotal clinical trials.
The big picture
Orchestra BioMed's addition to the Russell indexes reflects its growing market presence, supported by strategic partnerships and high-impact product candidates. The inclusion positions the company for greater visibility among institutional investors benchmarking against these widely followed indexes. Success hinges on the clinical and commercial progress of its flagship products in multi-billion-dollar markets.
What we're watching
- Clinical Progress
- The pace at which AVIM Therapy and Virtue SAB advance through pivotal clinical trials will determine commercialization timelines.
- Market Performance
- Whether Orchestra BioMed can sustain its market capitalization growth to maintain Russell index inclusion.
- Strategic Partnerships
- How the collaboration with Medtronic impacts the development and commercialization of AVIM Therapy.
Related topics